Hunault-Berger Mathilde, Chevallier Patrice, Delain Martine, Bulabois Claude-Eric, Bologna Serge, Bernard Marc, Lafon Ingrid, Cornillon Jérome, Maakaroun Abdallah, Tizon Alexandra, Padrazzi Bruno, Ifrah Norbert, Gruel Yves
Hematology Department of Angers, France.
Haematologica. 2008 Oct;93(10):1488-94. doi: 10.3324/haematol.12948. Epub 2008 Aug 25.
The effects of L-asparaginase on hemostasis during induction chemotherapy are less defined in adults than in children. We, therefore, studied the effects of L-asparaginase in adult patients.
This was a retrospective analysis of 214 patients treated with L-asparaginase (7500 IU/m(2) x 6) for acute lymphoblastic leukemia or lymphoblastic lymphoma. Between day 1 of the induction course and discharge, clinical events, and biological and therapeutic modifications were reviewed.
Antithrombin and fibrinogen levels were lower than 60% and 1 g/L in 71% and 73% of patients, respectively. Twenty thromboses occurred in 9.3% of the patients; these patients had a median antithrombin level of 53% (range, 21-111) at the time of the event. Forty-two episodes of bleeding occurred in 31 patients with a median fibrinogen level of 1.3 g/L. Infusions of L-asparaginase were reduced or delayed in 64% of patients due to low fibrinogen and/or antithrombin levels. Fresh-frozen plasma, antithrombin and fibrinogen were infused in 31%, 41% and 52% of patients, respectively. The mean antithrombin and fibrinogen levels increased from 61% to 88% and from 1 to 1.4 g/L after infusion of antithrombin or fibrinogen respectively, while both levels remained unchanged after the infusion of fresh-frozen plasma. In patients who received antithrombin concentrates L-asparaginase injections were less frequently omitted or delayed (53% vs. 72%, p=0.005), the rate of thrombosis was lower (4.8% vs. 12.2%, p=0.04) and the disease-free survival was also reduced (p=0.05).
This retrospective study suggests that antithrombin concentrates may have a beneficial effect on the outcome of adults treated for acute lymphoblastic leukemia with L-asparaginase; prospective studies are essential to confirm this hypothesis.
与儿童相比,左旋门冬酰胺酶在成人诱导化疗期间对止血的影响尚不明确。因此,我们研究了左旋门冬酰胺酶在成年患者中的作用。
这是一项对214例接受左旋门冬酰胺酶(7500 IU/m²×6)治疗急性淋巴细胞白血病或淋巴细胞淋巴瘤患者的回顾性分析。在诱导疗程的第1天至出院期间,对临床事件以及生物学和治疗方面的改变进行了回顾。
分别有71%和73%的患者抗凝血酶和纤维蛋白原水平低于60%和1 g/L。9.3%的患者发生了20次血栓形成;这些患者在事件发生时抗凝血酶水平的中位数为53%(范围为21 - 111)。31例患者发生了42次出血事件,纤维蛋白原水平的中位数为1.3 g/L。由于纤维蛋白原和/或抗凝血酶水平低,64%的患者减少或延迟了左旋门冬酰胺酶的输注。分别有31%、41%和52%的患者输注了新鲜冷冻血浆、抗凝血酶和纤维蛋白原。输注抗凝血酶或纤维蛋白原后,抗凝血酶和纤维蛋白原的平均水平分别从61%升至88%和从1 g/L升至1.4 g/L,而输注新鲜冷冻血浆后这两个水平均未改变。接受抗凝血酶浓缩物治疗的患者中,较少漏用或延迟注射左旋门冬酰胺酶(53%对72%,p = 0.005),血栓形成率较低(4.8%对12.2%,p = 0.04),无病生存率也有所降低(p = 0.05)。
这项回顾性研究表明,抗凝血酶浓缩物可能对接受左旋门冬酰胺酶治疗急性淋巴细胞白血病的成年患者的预后有有益影响;前瞻性研究对于证实这一假设至关重要。